eosinophilic asthma
Jump to navigation
Jump to search
Laboratory
- complete blood count
- eosinophil count > 150-300/uL
Management
- glucocorticoids for asthma exacerbations
- IL5-inhibitors
- mepolizumab may diminish exacerbations & the need for glucocorticoids[1]
- benralizumab (Fasenra)[4]
- reslizumab (Cinqair)
- omalizumab (Xolair)[3]
Notes
- editorialist notes that asthma exacerbations decreased by 50% with placebo in one study suggesting that frequent monitoring of patients may lead to better control without the need for expensive biologic therapy[1]
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 Ortega HG et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014 Sep 8; PMID: https://www.ncbi.nlm.nih.gov/pubmed/25199059
Bel EH et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014 Sep 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25199060
Nair P Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med 2014 Sep 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25197762 - ↑ Castro M, Corren J, Pavord ID et al Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. May 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29782217 Free full text https://www.nejm.org/doi/full/10.1056/NEJMoa1804092
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 4.0 4.1 From The Medical Letter on Drugs and Therapeutics Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA. 2018;319(14):1501-1502 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29634828 https://jamanetwork.com/journals/jama/fullarticle/2678013